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702Objective: Pulmonary endarterectomy is a curative surgical treatment option for themajority of patientswith chronic
thromboembolic pulmonary hypertension. The current surgical management and postoperative outcome of patients
enrolled in an international registry on chronic thromboembolic pulmonary hypertension were investigated.
Methods: The registry included newly diagnosed (6 months) consecutive patients with chronic thromboem-
bolic pulmonary hypertension from February 2007 to January 2009.
Results:A total of 679 patients were registered from 1Canadian and 26 European centers, of whom 386 (56.8%)
underwent surgery. Themedian age of patients undergoing surgery was 60 years, and 54.1%weremale. Previous
pulmonary embolismwas confirmed for 79.8% of patients. Perioperative complications occurred in 189 patients
(49.2%): infection (18.8%), persistent pulmonary hypertension (16.7%), neurologic (11.2%) or bleeding
(10.2%) complications, pulmonary reperfusion edema (9.6%), pericardial effusion (8.3%), need for extracorpo-
real membrane oxygenation (3.1%), and in-hospital mortality due to perioperative complications (4.7%). Docu-
mented 1-yearmortalitywas 7%. Preoperative exercise capacitywas predictive of 1-yearmortality. Postoperative
pulmonary vascular resistance predicted in-hospital and 1-year mortality. In patients evaluated within 1 year after
surgery, the median pulmonary vascular resistance had decreased from 698 to 235 dyn.s.cm5 (95% confidence
limit, 640–874 and 211–255, respectively, n¼ 70) and themedian 6-minutewalk distance had increased from362
to 459m (95% confidence limit, 340–399 and 440–473, respectively, n¼ 168).NewYorkHeartAssociation func-
tional class improved with most patients progressing from class III/IV to class I/II.
Conclusions: Pulmonary endarterectomy is associated with a low in-hospital mortality rate and improvements
in hemodynamics and exercise capacity. (J Thorac Cardiovasc Surg 2011;141:702-10)Earn CME credits at
http://cme.ctsnetjournals.org
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Abbreviations and Acronyms
CL ¼ confidence limit
CT ¼ computed tomography
CTEPH ¼ chronic thromboembolic pulmonary
hypertension
mPAP ¼ mean pulmonary artery pressure
NYHA ¼ New York Heart Association
OR ¼ odds ratio
PAH ¼ pulmonary arterial hypertension
PEA ¼ pulmonary endarterectomy
PVR ¼ pulmonary vascular resistance
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C
DCTEPH may develop in up to 4% of patients within
the first 2 years after acute pulmonary embolism,3 and
retrospective studies have described preceding venous
thromboembolism in up to 69% of cases.4 Left untreated,
the disease has a poor prognosis, proportional to the severity
of pulmonary hypertension.5
Surgical pulmonary endarterectomy (PEA) is recognized
as the standard treatment for CTEPH in most patients.6,7
The procedure involves the removal of fibrous obstructive
tissue from the pulmonary arteries during circulatory arrest
under deep hypothermia. The subsequent degree of relief of
pulmonary hypertension is variable, but in many cases may
be total with restoration of pulmonary hemodynamics to
normal or near normal. The decision to operate is made on
the basis of the severity of clinical symptoms, the amount
and surgical accessibility of the thromboembolic lesions,
the degree of impairment of pulmonary hemodynamics, and
the presence of comorbidities. However, persistent
pulmonary hypertension due to incomplete endarterectomy
or significant secondary vasculopathy is a potential
postoperative complication associated with increased
morbidity and mortality.6 Inoperable patients and patients
with persistent pulmonary hypertension might benefit from
medical treatment with drugs that are effective in pulmonary
arterial hypertension (PAH).8-10 However, exercise capacity
and survival have not been improved by targeted medical
therapy in randomized trials in patients with CTEPH.10
This report, based on a large-scale international prospec-
tive registry on CTEPH, documents the current surgical
management of patients with CTEPH using state of the
art medical care. Impact on postoperative hemodynamics
and outcome, and 1-year survival is investigated.
PATIENTS AND METHODS
Study Design
This prospective registry was designed to include newly diagnosed (6
months) consecutive patients with CTEPH in participating centers in Eu-
rope and Canada, from February 2007 to January 2009. The registry proto-
col did not interfere with the management of patients by their physician.
Formal ethics approvals were filed when required by country laws. This re-The Journal of Thoracic and Caport focuses on those patients who underwent PEA. The observation period
extended from inclusion into the registry until death/transplantation or up
to 1 year after PEA. Longer-term follow-up is currently ongoing.
Inclusion Criteria
At all participating institutions, the diagnosis of CTEPH was established
according to clinical guidelines valid at study initiation11 andwithin 6months
of inclusion in the registry. To qualify for inclusion, patients were to be 18
years or older and to have established pulmonary hypertension as confirmed
by mean pulmonary artery pressure (mPAP) 25 mm Hg or greater at rest or
30 mm Hg or greater after exercise and pulmonary capillary wedge pressure
15 mmHg or less during a right heart catheterization. CTEPHwas to be con-
firmedas the cause of pulmonaryhypertension byabnormalities inventilation/
perfusion scan (including at least 1 mismatched segmental perfusion defect),
computed tomography (CT) scan, or pulmonary angiography. Abnormal CT
scan/pulmonary angiography demonstrated proximal lesions (webs, bands,
and narrowed vessels). Before diagnosis, patients were required to have at
least 3 months of anticoagulation therapy and no PAH-specific treatment.
Data Collection
Data collected in this registry were obtained from assessments routinely
performed for patients with CTEPH in clinical practice and included med-
ical history, clinical signs and symptoms, diagnosis, and treatment proce-
dures. The latest assessments of hemodynamics, exercise capacity, and
New York Heart Association (NYHA) class, performed within 1 year after
surgery, were analyzed.
Surgery
The PEA procedurewas performed according to the principles previously
described.6 Criteria for inoperability included distal pulmonary artery ob-
structions, imbalance between severity of pulmonary hypertension and mor-
phologic lesion, PVR greater than 1500 dyn.s.cm5, age, and comorbidity.
Persistent pulmonary hypertension after PEAwas defined as mPAP greater
than 25 mm Hg or echocardiographic systolic PAP greater than 40 mm Hg.
Statistical Analysis
Data analysis was performed using the SAS software package version
9.2 (SAS Institute Inc, Cary, NC).
Quantitative variables were described using median, minimum and
maximum, and 95% confidence limit (CL). Wilcoxon 2-sample test was
used for comparing continuous variables, and Fisher’s exact test was
used for categoric variables. All inferential statistical analyses were per-
formed in an exploratory sense.
Univariate and multivariate logistic regressions were used to identify
risk factors for mortality among the following parameters: confirmed pul-
monary embolism, time from symptoms to PEA and from last pulmonary
embolism to PEA, NYHA class, 6-minute walk distance, mPAP, PVR, ini-
tiation of PAH-specific treatment at diagnosis, circulatory arrest duration,
change in PVR from diagnosis to end of intensive care, PVR at end of
intensive care, and number of PEAs performed by center. Results are pre-
sented as odds ratios (OR) with corresponding 95% CL (calculated using
the Wald chi-square test).RESULTS
All-Patient Population (n ¼ 679)
From February 2007 to January 2009, 679 consecutive
patients recently diagnosed (6 months) with CTEPH
were prospectively enrolled in 1 Canadian and 26 European
centers, of whom 386 (56.8%) underwent surgery in 17
centers (2 patients underwent operation in 2 nonparticipat-
ing centers). On the basis of the surgeon’s assessment, 427rdiovascular Surgery c Volume 141, Number 3 703
TABLE1. Patients’ characteristics at diagnosis and surgery parameters
Operated patients
(n ¼ 386)
Gender (% male) 54.1%
Ethnicity (% white) 94.6%
Age (y) 60 (18–84)
Weight (kg) 76 (38–140)
NYHA class (%III/%IV) 67.9/12.7
6MWD (m) 341 (20–700) (n ¼ 336)
mPAP* (mm Hg) 48 (17–80) (n ¼ 382)
PVRy (dyn.s.cm5) 728 (97–2880) (n ¼ 340)
Cardiac index (L.min1.m2) 2.2 (0.9–7.0) (n ¼ 363)
Time from symptoms to diagnosis (mo) 14.6 (0.5–440.7) (n ¼ 372)
Time from diagnosis to PEA (d) 78 (0–588)
Time from symptoms to PEA (y) 1.5 (0.1–36.7) (n ¼ 372)
Time from last PE to PEA (y) 1.2 (0.0–33.8) (n ¼ 265)
Circulatory arrest duration (min) 35 (0–146) (n ¼ 378)
Median mechanical ventilation time (d) 1.2 (0–45) (n ¼ 381)
Vena cava filter or clip (% patients) 40.2% (n ¼ 356)
PVR at end of intensive care (dyn.s.cm5) 248 (32–1440) (n ¼ 280)
6MWD, 6-minute walk distance; mPAP, mean pulmonary artery pressure; NYHA,
NewYork Heart Association; PE, pulmonary embolism; PEA, pulmonary endarterec-
tomy; PVR, pulmonary vascular resistance. Values are expressed as medians with
ranges or percentages; n: patients with assessment. *mPAP: 9 values<25 mm Hg;
3 values>75 mm Hg. yPVR: 13 values<200 dyn.s.cm5
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Dpatients (62.9%) were considered operable. Eventually, 386
patients (56.8%) underwent surgery, including 13 patients
documented as nonoperable; 38 operable patients refused
the procedure, and 7 patients died before surgery.
Operated Patient Population (n ¼ 386)
The operated patients had a median age of 60 years, and
54.1% were male (Table 1). The median time from first
symptoms to diagnosis was 14.6 months. Patients presented
with dyspnea (99.2%), edema (40.7%), fatigue (29.5%),
chest pain (16.6%), and syncope (16.1%).
Medical history was supportive of the thromboembolic
origin of CTEPH. Previous single or recurrent pulmonary
embolism was confirmed for 79.8% of all patients. CTEPH
was diagnosed at a median of 12.1 months (range: 0–399
months) after the last pulmonary embolism event. Previous
deep vein thrombosis was documented in 59.6% of patients
(n ¼ 155/260).
Right heart catheterization (Table 1) indicated significant
pulmonary hypertension with elevated PVR (median: 728
dyn.s.cm5, mean: 799 dyn.s.cm5) and mPAP (median and
mean: 48 mm Hg). Perfusion scans were abnormal in
99.4% of patients (n¼ 308/310), and ventilation scans were
abnormal in 16.4% of patients (n¼ 47/287). Among patients
with an abnormal perfusion scan, 5%/4% had a total right/left
lung perfusion defect, and among patients with reported mis-
matches, 94%/90% had more than 1 segmental mismatch in
the right/left lung and92%/93% hadmore than 2 subsegmen-
tal mismatches in the right/left lung. Pulmonary angiography
demonstrated proximal lesions of the pulmonary artery up to704 The Journal of Thoracic and Cardiovascular Surgthe segmental level in 69.5% of patients (n ¼ 226/325).
Among patients with reported data, lesions were located in
the right/left main pulmonary artery (16%/13%), lobar ar-
teries (72%/56%), or segmental arteries (51/57%). This
was supported by CT, which similarly indicated proximal le-
sions of the pulmonary artery up to the segmental level in
69.1% of patients (n¼ 217/314). CTalso indicated dilatation
of bronchial arteries in 77.0% of patients (n¼ 154/200) and
mosaic perfusion pattern in 82.2% of patients (n¼ 199/242).
At CTEPH diagnosis, 27.7% of the patients initiated at
least 1 PAH-specific therapy, including phosphodiesterase
type V inhibitor (15.0%), endothelin receptor antagonist
(11.9%), prostacyclin analogue (2.6%), and combined
treatment (1.8%).
Surgery
The median time from CTEPH diagnosis to surgery was
78 days. In the subgroup of patients initiating PAH-specific
therapies at diagnosis, surgery was delayed (122 vs 62 days,
P < .0001, Wilcoxon–Mann–Whitney test) and the in-
hospital death rate was higher (8.4% vs 3.2%, nonsignifi-
cant, Fisher’s exact test). Both observations may be related
to the higher PVR reported in these patients at diagnosis
compared with untreated patients (876 vs 699 dyn.s.cm5,
P ¼ .0005) (adjustment for cofactors was not performed).
PEA was considered ‘‘complete’’ by the surgeon in
93.7% of patients, and the median duration of circulatory
arrest was 35 minutes (Table 1). An inferior vena cava filter
was placed in 40.2% of patients, and an additional cardiac
procedure (patent foramen ovale/atrial septal defect clo-
sure, n¼ 20; coronary artery bypass graft, n¼ 19; tricuspid
valve repair, n¼ 4; aortic or mitral valve surgery, n¼ 2; re-
moval of right ventricular mass clot, n ¼ 1; and other,
n ¼ 13) was performed in 15.6% of patients (n ¼ 59/
379). Perioperative treatments were documented in 252 pa-
tients, including catecholamines (90.5%), nitric oxide
(21.4%), phosphodiesterase type III inhibitors (13.1%),
prostanoids (11.2%), and aprotinin (6.7%).
Surgical Complications
Of384evaluableoperatedpatients, 189 (49.2%) hadaperi-
operative complication, including infection (18.8%, ofwhom
65.7% had ventilator-acquired pneumonia, 6.0% hadmedia-
stinitis, 4.5% had catheter-related sepsis, and 31.3% had
other), persistent pulmonary hypertension (16.7%), neuro-
logic (11.2%) or bleeding (10.2%) complications, pulmo-
nary reperfusion edema (9.6%), pericardial effusion
(8.3%), or need for extracorporeal membrane oxygenation
(3.1%); 18 patients died in hospital after surgery (4.7%).
The occurrence of neurologic complications increased
with increasing circulatory arrest time: 1.9% less than 20
minutes (n ¼ 52, including 7 patients with no arrest
time), 10.8% for 21 to 40 minutes (n ¼ 185), 14.6% for
41 to 60 minutes (n ¼ 103), and 18.4% greater than 60ery c March 2011
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a risk factor for developing neurologic complications:
The OR for comparison of circulatory arrest time less
than 20 minutes with more than 60 minutes was 0.09
(95% CL, 0.01–0.74). Three patients had irreversible com-
plications (cerebrovascular accident, n ¼ 2; and worsening
of preexisting schizophrenia, n¼ 1]) despite circulatory ar-
rest durations comparable to the median observed for the
whole population.
In-Hospital and One-Year Mortality
Within 1 year after PEA, 27 patients (7%) had died (64
had<1 year of follow-up); 18 died of perioperative compli-
cations and 9 died of various causes (trauma, malignancy,
multiorgan failure, pneumonia, meningitis, infection, acute
respiratory distress syndrome, renal failure, and sudden
death). One patient underwent lung transplantation.
Univariate analysis revealed that PVR and 6-minute walk
distance at diagnosis and PVR at end of intensive care were
associated with in-hospital and 1-year mortality; time from
the last pulmonary embolism to PEA and initiation of PAH-
specific treatment at diagnosis were also risk factors for in-
hospital death. Multivariate analysis further identified PVR
at the end of intensive care as an independent risk factor for
in-hospital death (OR, 1.79; CL, 1.11–2.88 per 100TABLE 2. Comparison of parameters for survivors and nonsurvivors in-h
In-hospital nonsurvivo
(n ¼ 18)
Time until PEA (y)
From symptoms 1.1
(0.7–15.6)
n ¼ 15
From last pulmonary embolism 5.0
(0.2–29.2)
n ¼ 8
Diagnosis characteristics
6MWD (m) 290
(110–500)
n ¼ 15
mPAP (mm Hg)* 52
(46–75)
n ¼ 18
PVR (dyn.s.cm5)y 1091
(416–2682)
n ¼ 15
Peri/postoperative characteristics
Duration of circulatory arrest (min) 42
(10–87)
n ¼ 18
PVR at the end of intensive care (dyn.s.cm5) 400
(191–1432)
n ¼ 11
6MWD, 6-minute walk distance; mPAP,mean pulmonary artery pressure; PEA, pulmonary
with range, n. See text for ORs. *mPAP: 9 values<25 mm Hg; 3 values>75 mm Hg. yP
The Journal of Thoracic and Cadyn.s.cm5) and for death at 1 year (OR, 1.40; CL, 1.08–
1.83 per 100 dyn.s.cm5). The 6-minute walk distance at di-
agnosis was also an independent factor for death at 1 year
(OR, 0.40; CL, 0.21–0.79 per 100m). Survivors had a higher
6-minute walk distance and a lower PVR at diagnosis than
nonsurvivors (Table 2). Mortality rates, in-hospital and at 1
year, increased with increasing values of PVR at diagnosis
(Table 3) to reach 10.6% and 12.8%, respectively, for those
patients with a PVR exceeding 1200 dyn.s.cm5. However,
neither the mPAP at diagnosis nor the magnitude of the
decrease in PVR achieved after PEA was identified as
a risk factor.
The mortality rate tended to be higher in patients with no
history of pulmonary embolism; it increased with increas-
ing NYHA functional class at diagnosis and with circula-
tory arrest duration (Table 3), but these parameters were
not risk factors, nor was the time elapsed from onset of
symptoms to PEA (Table 2). The presence of an inferior
vena cava filter had no obvious effect on the mortality at
1 year (Table 3).
No death was recorded among patients with splenectomy
(n¼ 7) or ventriculoatrial shunt (n¼ 3). However, the pres-
ence of coronary disease or myocardial infarction and
thrombophilic disorder was related to increased in-
hospital and 1-year death (Table 3).ospital and at 1 year
rs In-hospital survivors
(n ¼ 368)
1-y
nonsurvivors
(n ¼ 27)
1-y survivors
(n ¼ 359)
1.6
(0.1–36.7)
n ¼ 357
1.2
(0.7–15.6)
n ¼ 24
1.5
(0.1–36.7)
n ¼ 348
1.2
(0.0–33.8)
n ¼ 257
3.0
(0.2–29.2)
n ¼ 14
1.2
(0.0–33.8)
n ¼ 251
350
(20–700)
n ¼ 321
280
(50–500)
n ¼ 23
351
(20–700)
n ¼ 313
48
(17–80)
n ¼ 364
51
(31–75)
n ¼27
48
(17–80)
n ¼ 355
712
(97–2880)
n ¼ 325
905
(320–2682)
n ¼ 24
715
(97–2880)
n ¼ 316
35
(0–146)
n ¼ 360
41
(10–87)
n ¼ 25
35
(0–146)
n ¼ 353
245
(32–1440)
n ¼ 269
260
(164–1432)
n ¼ 19
245
(32–1440)
n ¼ 261
endarterectomy; PVR, pulmonary vascular resistance. Values are expressed as median
VR: 13 values<200 dyn.s.cm5
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TABLE 3. Impact of specific parameters on in-hospital death and death at 1 year
In-hospital deaths
n (%)
Deaths at 1 year
n (%)
PVR (dyn.s.cm5), n ¼ 340
<400 n ¼ 48 0 (0%)* 1 (2.1%) NS
400–800 n ¼ 141 4 (2.8%)* 8 (5.7%) NS
800–1200 n ¼ 104 6 (5.8%) NS 9 (8.7%) NS
>1200 n ¼ 47 5 (10.6%)y 6 (12. 8%)y
NYHA functional class, n ¼ 386
I and II n ¼ 75 0z 2 (2.7%) NS
III n ¼ 262 12 (4.6%)* 19 (7.3%) NS
IV n ¼ 49 6 (12.2%)y 6 (12.2%)y
History of confirmed pulmonary embolism, n ¼ 386
Yes n ¼ 308 12 (3.9%) NS 19 (6.2%) NS
No n ¼ 78 6 (7.7%)y 8 (10.3%)y
Presence of an inferior vena cava filter, n ¼ 298
Yes n ¼ 42 — 2 (4.8%) NS
No n ¼ 256 — 14 (5.5%)y
Circulatory arrest duration, n ¼ 378
 20 min n ¼ 52 2 (3.8%) NS 4 (7.7%) NS
21–40 min n ¼ 185 5 (2.7%) NS 9 (4.9%) NS
1–60 min n ¼ 103 8 (7.8%) NS 11 (10.7%) NS
>60 min n ¼ 38 3 (7.9%)y 3 (7.9%)y
Presence of coronary disease or myocardial infarction, n ¼ 276
Yes n ¼ 40 4 (10.0%)* 6 (15%)*
No n ¼ 236 5 (2.1%)y 12 (5.1%)y
Presence of thrombophilic disorder, n ¼ 254
Yes n ¼ 141 7 (5.0%) NS 13 (9.2%) NS
No n ¼ 113 2 (1.8%)y 4 (3.5%)y
PVR, Pulmonary vascular resistance; NS, not significant; NYHA, New York Heart Association. Values are presented as numbers of patients (percentages per category). *P<.05
compared with y. zP<.005 compared with y. NS compared with z (Fisher’s exact test)
FIGURE 1. NYHA functional class before surgery and within 1 year after
surgery (n ¼ 221).
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After surgery, hemodynamics and symptoms were mark-
edly improved for patients with an assessment within 1 year
after PEA: Themedian PVR decreased from 736 dyn.s.cm5
before surgery to 248 dyn.s.cm5 at the end of intensive care
(95% CL, 702–827 and 230–263, respectively, n ¼ 252)
and from 698 dyn.s.cm5 to 235 dyn.s.cm5 within 1 year af-
ter surgery (95% CL, 640–874 and 211–255, respectively,
n ¼ 70). The median 6-minute walk distance increased
from 362 to 459 m (95% CL, 340–399 and 440–473, re-
spectively, n¼ 168). NYHA functional class also improved
with patients progressing from class III and IV to class I and
II (Figure 1). At the end of intensive care, 64 patients
(16.7%) had persistent postoperative pulmonary hyperten-
sion. These patients had a particularly compromised preop-
erative hemodynamic status, which was considerably
improved by surgery: The median PVR decreased from
937 dyn.s.cm5 before surgery to 396 dyn.s.cm5 at the
end of intensive care (95% CL, 822–1120 and 320–450, re-
spectively, n ¼ 49). The median 6-minute walk distance
tended to increase from 288 to 385mwithin 1 year after sur-
gery (95% CL, 250–362 and 324–480, respectively,
n ¼ 25).706 The Journal of Thoracic and Cardiovascular SurgCenter Expertise
Of 386 operated patients, 141 (36.5%) underwent opera-
tion in centers performing more than 50 PEAs per year
(based on data from 2004–2006) (Table 4). In these centers,
the mortality rates tended to be lower, but the magnitude of
the decrease in PVR achieved after surgery was less when
compared with that of centers performing fewer PEAs per
year. However, the center expertise as defined by theery c March 2011
TABLE 4. Center expertise and surgical management
Average no. of PEAs per year
1–10 11–50 >50 Combined
No. of centers performing PEA, n (%) 6 (35.3%) 8 (47.1%) 3 (17.6%) 17*
No. of patients, n (%) 54 (14.0%) 191 (49.5%) 141 (36.5%) 386*
Change in PVR from diagnosis to end of intensive
care, dyn.s.cm5, median (range), n
476 NS
(1760 to 80)
n ¼ 43
476y
(2256 to 22)
n ¼ 144
400z
(2261 to 554)
n ¼ 65
457
(2261 to 554)
n ¼ 252
Death, n (%)x
In-hospital 4 (7.4%) NS 9 (4.7%) NS 5 (3.5%)x 18 (4.7%)
1 y after PEA 6 (11.1%) NS 14 (7.3%) NS 7 (5.0%)x 27 (7.0%)
NS, Not significant; PEA, pulmonary endarterectomy; PVR, pulmonary vascular resistance. *Two patients underwent operations in 2 nonparticipating centers performing>50
PEAs per year and<10 PEAs per year, respectively. NS compared with z (Wilcoxon 2-sample test) or x (Fisher’s exact test). yP<.05 compared with z (Wilcoxon 2-sample test).
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mortality.
DISCUSSION
This study, based on a large-scale international prospec-
tive non-interventional registry on incident CTEPH cases,
documents the current surgical management and outcome
of patients undergoing PEA in Europe and Canada. Previ-
ously, large patient series have been derived retrospectively
from medical and surgical databases from San Diego and
Paris,6,7 with 2 recent reports including a PAH-controlled
cohort study in Europe4 and a national registry in the United
Kingdom.12 The present investigation supports the role of
exercise capacity in predicting 1-year mortality and of post-
operative PVR as a predictor of in-hospital and 1-year mor-
tality in patients with CTEPH.
The demographics of the operated patients with CTEPH
included in the registry are in line with previous re-
ports.6,7,13,14 CTEPH was almost equally frequent in men
and women in their sixth decade of life. The greater than
usual occurrence of pulmonary embolism and deep vein
thrombosis7 has also been observed in recent studies4 and
may have resulted from increased awareness of thrombosis
in the participating centers.
The University of California San Diego has performed the
most PEA procedures in the world and has set the surgical
standards.The standard technique,6 followedbymost centers,
involves cooling to 20C with periods of circulatory arrest to
allow a clear operative field for distal endarterectomy. The
fundamental compromise is between allowing enough arrest
time for a complete endarterectomy and limiting the time of
circulatory arrest.With relatively short arrest periods (20min-
utes per side), permanent cerebral damage is rare after PEA
surgery. However, the duration of circulatory arrest is associ-
ated with the incidence of temporary neurologic dysfunction
in patients undergoing aortic surgery.15,16 Reich and
colleagues15 reported that a circulatory arrest of 25 minutes
or more was associated with memory and fine motor deficits.
Our study has demonstrated that an increased duration of cir-
culatory arrest during PEA surgery is a risk factor for devel-The Journal of Thoracic and Caoping neurologic complications. However, most neurologic
complications were temporary, and, as previously reported,17
the use or duration of circulatory arrest did not affect mortal-
ity, but failure to reduce PVR did.6,14 Although the median
duration of total circulatory arrest was only 35 minutes,
some patients did not have any arrest time and others had
a cumulative time maximum of 146 minutes. These
extremes arose because 1 center used a technique to try and
avoid arrest and another used multiple very short periods.
Modifications of the PEA procedure intended to avoid
circulatory arrest have been described18 but have not been
demonstrated to provide substantial benefit when compared
with the traditional technique.
The current PEA procedure provides remarkable results,
with an in-hospital mortality rate in recent worldwide series
ranging from 4.4% to 16%.6,13,14,19,20 The low mortality
rate (4.7%) reported is in line with continuously improving
surgical results due to a combination of increased
experience and adequate selection of surgically eligible
patients. The inclusion of exclusively newly diagnosed
patients into the registry may also have contributed to the
low mortality rate observed. Mortality tended to be lower in
high-volume centers despite a lower decrease in PVR; it is
possible that small centers performed operations in patients
with proximal disease and successfully decreased PVRwhile
referring the more distal cases to larger centers.
Postoperative PVR was found to be an independent risk
factor for in-hospital and 1-year mortality, whereas preoper-
ative PVR was only identified in univariate analysis. Most
studies have associated high preoperative PVR (ie,>900–
1100 dyn.s.cm5) with increased PEA mortality.6,7,12,17 As
reported in 1 series,7 we observed an almost linear relation-
ship between preoperative PVR and in-hospital mortality.
Mortality is also strongly related to the postoperative
PVR, and a decrease to less than 500 dyn.s.cm5 has been
reported as optimal.6,14 The present registry confirms that
the best operative outcome requires significant early
reduction of PVR.
The 6-minute walk test is a well-established prognostic
tool in idiopathic PAH,21 but it has not been validated inrdiovascular Surgery c Volume 141, Number 3 707
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with CTEPH with exercise capacity.12,22 In the present
registry, nonsurvivors had a worse preoperative 6-minute
walk distance than survivors and exercise capacity was
predictive of 1-year mortality.
The time from last pulmonary embolism to PEA was
a risk factor for in-hospital mortality in univariate analysis.
Because the triggering event in the development of CTEPH
is an unresolved pulmonary embolism in many patients,
earlier referral to surgery after such an event might avoid
the occurrence of a secondary vasculopathy in the unaf-
fected areas of the pulmonary vascular tree.
Excessive perioperative mortality in patients with CTEPH
with specificmedical conditions, such as splenectomy, ventri-
culoatrial shunt, and infected pacemaker,19 has not been
systematically reported.12 In the present registry, no death
cases were reported for patients with these conditions,
although the presence of coronary disease,myocardial infarc-
tion, or thrombophilic disorder was associatedwith increased
mortality.
Among survivors, most of the improvement in hemody-
namics was achieved immediately after PEA, as an immedi-
ate result of the relief of central mechanical obstruction. The
most impressive aspect of the postoperative outcomewas the
improvement of clinical symptoms; the majority of patients
improved their walk distance and returned to NYHA class I
or II during the first year after surgery. This immediate and
sustained benefit from surgery has been reported in individ-
ual series bynumerousgroups throughout theworld,13,14,20,23
demonstrating that postoperative normalization of
hemodynamic and functional status could be achieved.
However, despite careful patient selection based on the
anticipated hemodynamic improvement, the postoperative
PVR failed to return to normal or near normal levels by the
end of intensive care in 16.7% of patients. Improvement
may not have been sufficient in these patients with more
compromised hemodynamics and exercise capacity at
diagnosis. They may have more vasculopathy6 preventing
them from receiving the full benefit from surgery.
Over the last decade, several novel therapies have been
developed for PAH, including prostacyclin analogs, endo-
thelin receptor antagonists, and phosphodiesterase type V
inhibitors.8-10 Evidence of efficacy in PAH, coupled with
studies showing histopathologic similarities between
CTEPH and PAH, has provided a rationale to extend the
use of these medications to the treatment of CTEPH.7
As a consequence, the prescription of these medications,
even in operable CTEPH, has increased over the past sev-
eral years. In the UK registry,12 29% of the surgical pa-
tients received PAH-specific therapy before surgery
during the period 2001–2002, compared with 65% for
the period 2003–2006. Jensen and colleagues24 reported
an increase from 19.9% in 2005 to 37% in 2007. We sim-
ilarly observed that 27.7% of the surgical patients initiated708 The Journal of Thoracic and Cardiovascular Surgat least 1 PAH-specific therapy at diagnosis. Selected
‘‘high-risk’’ patients might benefit from PAH-specific ther-
apies to optimize pulmonary hemodynamics before sur-
gery. Moreover, in patients whose surgery is delayed
owing to limited medical resources, pretreatment may pre-
vent clinical deterioration. Several open-label studies sug-
gest a beneficial effect for patients with severe CTEPH
waiting for surgery who are treated with prostacyclin8 or
bosentan.25 However, although the benefits of preoperative
medical treatment have to be confirmed, the risks may in-
clude unnecessary delays to a potentially curative surgical
intervention.CONCLUSIONS
This contemporary registry highlights current practice and
surgical management of patients with CTEPH. The PEA sur-
gery was associated with a low in-hospital mortality rate and
improvements in hemodynamics and exercise capacity. The
duration between last pulmonary embolism and PEA was
identified as a risk factor for in-hospital mortality, thus
emphasizing the importance of early referral to surgery. Pre-
operative exercise capacity was independently predictive of
1-yearmortality,whereas postoperative PVRwas an indepen-
dent factor of in-hospital and 1-year mortality. Whether the
contemporary management of patients with CTEPH yields
a better prognosis than observed in the past will be evaluated
in the ongoing 3-year follow-up of this large patient cohort.
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Dr Thoralf Sundt (Rochester, Minn). I have a few questions for
you. First, I congratulate you on doing such a multicenter study,
and those who have attempted to do even a registry like this can
appreciate the complexity of it. This is a complex condition, and
if we are going to make progress, we do need to do these kinds
of studies, but it is a lot of work just to collect the information. I
tip my hat to you on that, and really with a remarkably low mortal-
ity rate.
I have a fairly technical question. In our institution, it is almost
impossible anymore to get the interventional radiologists to do an
adequate pulmonary angiogram, and they have themselves begged
us to use high-resolution CT scanning, and we have basically aban-
doned pulmonary arteriography in favor of CT scanning with re-
constructions. I wonder if the same is true in Europe.
Dr Mayer. I have to disagree. I believe that for an adequate
evaluation of operability, pulmonary angiography is still the stan-
dard technique, and I do believe that CT angiography, even high-
resolution CT, 256-row CT, is not an adequate procedure, because
most of the radiologists believe they have to show clot in the
pulmonary arteries, but we are not speaking about clot, we are
speaking about 1-mm obstructions in segmental arteries. So it
might be possible to use it in central disease, but it is not possible
to use it in peripheral distal disease.
Dr Sundt. The second question relates to the learning curve.
You have a large number of patients but also a large number of cen-
ters, and you showed us the relationship betweenmortality rate and
center experience, but what about surgeon experience? Certainly
for me this has been a difficult operation with a steep learning
curve, and I still believe I am on that learning curve. I wonder if
you have any information about the relationship on a surgeon-
by-surgeon basis related to the learning curve, not just for mortal-
ity rate but residual PVR and, for that matter, the judgment about
operability.
Dr Mayer. We do not have the data for the whole registry. We
have the data for single centers. But notably, in the registry, you
had a look at the article, we could demonstrate that the centers
with low volume had a better postoperative PVR reduction com-
pared with the centers with high volume, probably because of
the intense selection of proximal candidates. So in centers
with high volume, many distal endarterectomies are performed
with some grade of microvascular disease, and therefore the
decrease of PVR might not be as hard compared with proximal
disease.
We know that the learning curve is intense, not only for the
surgeon but also for the people who make the evaluation and for
postoperative care, but we don’t have the data for the whole
registry.rdiovascular Surgery c Volume 141, Number 3 709
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yesterday about regionalization of lobectomy in Canada and in
this same vein in terms of the learning curve. Do you think a rela-
tively uncommon procedure like this should be done in only a few
centers, in a center of excellence type model, or what is your view
on that?
Dr Mayer. I think this operation should be performed only in
excellent centers, and the situation in Europe is very different.
For example, in England and France, there is only 1 center. Every
patient with CTEPH who undergoes an operation is referred to
Paris or Cambridge. In other countries there are centers with
high volume, but there are also several centers doing 2 or 3 cases
per year. This is not a good idea, because 1 death of 3 cases is 33%.
DrMichael Madani (San Diego, Calif). As you know, we have
been performing pulmonary endarterectomies for more than 2 de-
cades now, and we have done more than 2500 of these cases. It is
clear that this condition is still severely underdiagnosed and a large
number of patients are being denied surgery, even after the diagno-
sis is made.What is really disturbing, in the United States, and per-
haps more in Europe, is a wider application of the newer
vasodilator and antiproliferative agents preventing or delaying sur-
gical referrals. Although I agree that there may be eventually a role
for these agents in patients with residual pulmonary hypertension
after PEA or in preoperative patients when there is a severe mis-
match between clot burden and degree of pulmonary hypertension,
the bottom line is that this is a mechanical condition and requires
a mechanical solution.
The issue of operability is really the key issue of my discussion.
We believe that if there is evidence of thromboembolic disease,
surgery should be performed. This is particularly important, as
you just mentioned, with the CT scan, as well as the angiogram,
because most preoperative studies tend to underestimate the true
clot burden.We have found that more than 90% of patients referred
to us who are deemed inoperable at other centers or because they
have so-called distal disease really experience significant hemody-
namic improvement after full endarterectomy. The mortality rate
in the last 500 in our series is less than 3%. I would like to know710 The Journal of Thoracic and Cardiovascular Surghow this registry will address this issue of inoperability among
the 17 centers, including those with such low volumes?
Dr Mayer. The problem is that it was a noninterventional reg-
istry, so we took the data from the different centers. I completely
agree that the evaluation of operability is also a factor of learning
curve, and it is the same in our center, that many patients are sent
deemed inoperable, and they are clearly operable because some-
times they even have poor diagnostics. I do believe that every pa-
tient with diagnosed CTEPH should be referred to a surgical center
without delay and without medical treatment. There are no data
supporting preoperative medical treatment.
Dr Madani. I have one more question for you. I noticed in the
article that you used a PVR of 1500 as the cutoff for operability and
that in your data you had patients with higher PVRs. If you could
clarify why you are using a PVR of 1500 as a cutoff?
DrMayer.No, we are not using a PVR of 1500.Wewere asking
the surgeons why they did not perform PEA, and we were
asking for reasons, and one reason was very high PVR. Patients
with high PVRs, as seen in the numbers, were not excluded from
surgery.
Dr R. Duane Davis (Durham, NC). The incidence of acute lung
injury or ischemia-reperfusion or whatever you want to call it
seemed to be dramatically decreasing over the time. Is this a learn-
ing effect or the application of essentially the reperfusion strate-
gies that we use in lung transplant? Have you standardized that
across the centers or are you using this platform to improve process
across the centers in terms of an educational standpoint?
DrMayer. That is what wewant to do. Wewant to use this plat-
form for future studies, because there are no studies on periopera-
tive treatment at the moment. And it is true, over the last 20 years,
reperfusion lung injury has been significantly decreased and is not
a clinically significant problem anymore. We don’t know the exact
reasons for that, but we believe that a faster operation and better
postoperative care with regard to hemodynamics (eg, keeping
the cardiac index low) are good measures to reduce pulmonary re-
perfusion edema, but it is a multifactorial development. But it has
decreased significantly, you are right.ery c March 2011
